Alcohol Use and Incarceration Adversely Affect HIV-1 RNA Suppression among Injection Drug Users Starting Antiretroviral Therapy

Journal of Urban Health

Volumn 80, Issue 4, 2003, Pages 667-675

  Palepu, Anita ^a,b   Tyndall, Mark W ^a   Li, Kathy ^a   Yip, Benita ^a   O'Shaughnessy, Michael V ^a   Schechter, Martin T ^a   Montaner, Julio S G ^a   Hogg, Robert S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

Alcohol; Anti HIV agents; HIV infections; Human; Intravenous; Logistic regression models; Prison; Substance abuse

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOL CONSUMPTION; ARTICLE; DEMOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISON; SELF REPORT;

ADULT; ALCOHOL DRINKING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; PATIENT COMPLIANCE; PRISONS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0742270855     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jtg073     Document Type: Article

References (34)

1. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquired Immune Defic Syndromes. 2001;27(3):251-259.
2. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767-774.
3. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377-381.
4. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34(4): 511-518.
5. Maruschak LM. Bureau of Justice Statistics Bulletin: HIV in Prisons and Jails, 1999. Document NCJ 187456, 2001. Available at ojp.usdoj.gov/bjs/pub/hivpj99.pdf. Accessed November 11, 2003.
6. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59-65.
7. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547-549.
8. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283(3): 381-390.
9. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15(3):423-424.
10. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response [letter]. J Acquir Immune Defic Syndr. 2000;23(4):360-361.
11. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7): 1051-1058.
12. Fabris P, Tositti G, Manfrin V, et al. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? J Acquir Immune Defic Syndr. 2000;25(1):92-93.
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74-80.
14. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol. 2002;63(2):179-186.
15. Sanchez-Craig M, Wilkinson DA, Davila R. Empirically based guidelines for moderate drinking: 1-year results from 3 studies with problem drinkers. Am J Public Health. 1995;85(6):823-828.
16. Barbor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1992.
17. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83-88.
18. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3): 305-312.
19. Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476-1481.
20. White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. Int J STD AIDS. 2001;12(6):380-385.
21. Kim JY, Rich J, Zeiler S, et al. Successful community follow-up and reduced recidivism of HIV positive women prisoners. J Correctional Health Care. 1997;4:1-9.
22. Stein MD, Urdaneta ME, Clarke J, et al. Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addictive Dis. 2000;19(1):85-94.
23. Clarke SM, Mulcahy FM. Antiretroviral therapy for drug users. Int J STD AIDS. 2000;11(10):627-631.
24. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707-1715.
25. Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr. 2001;27(1):20-29.
26. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26(2):195-205.
27. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13(8):957-962.
28. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000;20(1):93-94.
29. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51(3):213-217.
30. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27(2):153-160.
31. Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug Alcohol Depend 2000;60(1):51-54.
32. Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38(9):911-925.
33. Raboud JM, Rae S, Vella S, et al. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. J Acquir Immune Defic Syndr. 1999;22(3):260-266.
34. Havlir D, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286(2):171-179.